PKM and neoplasm: Cancer cells often undergo a PKM2/PKM1 isoform switch, favouring the expression of PKM2, which supports the unique metabolic needs of tumour cells by allowing them to adjust pyruvate kinase activity according to cellular conditions [48, 49].